Results 211 to 220 of about 48,812 (228)

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

Cancer Cell, 2018
Joseph Szustakowski, Naiyer A Rizvi, Matthew D Hellmann   +2 more
exaly  

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab

Annals of Oncology, 2016
Maresa Altomonte, Michele Del Vecchio, Sara Gandini   +2 more
exaly  

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

Annals of Oncology, 2013
Michele Maio, Keisho Chin, Bart Neyns
exaly  

Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma

Annals of Oncology, 2013
Michele Del Vecchio, Lorenza Di Guardo, Riccardo Danielli   +2 more
exaly  

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†

Annals of Oncology, 2013
Igor N. Bondarenko, A Luft, T J Lynch
exaly  

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study

Annals of Oncology, 2015
Michele Del Vecchio, Michele Maio
exaly  

Ipilimumab

Reactions Weekly, 2022
openaire   +1 more source

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

Investigational New Drugs, 2010
Anna C Pavlick, Jeffrey S Weber, Lee Cranmer   +2 more
exaly  

An immune-active tumor microenvironment favors clinical response to ipilimumab

Cancer Immunology, Immunotherapy, 2011
Omid Hamid, Scott Chasalow, John Cogswell   +2 more
exaly  

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma

European Journal of Cancer, 2017
Richard W. Joseph, Ralf Gutzmer, Lisa A Kottschade   +2 more
exaly